Structure Therapeutics Inc. SEC filings document a Cayman Islands clinical-stage biopharmaceutical issuer whose Nasdaq-listed American depositary shares each represent three ordinary shares. The filings identify the company’s ADS and ordinary-share structure, Exchange Act reporting status, material agreements, and formal corporate-governance matters.
Recent 8-K reports cover financial results and corporate updates, Regulation FD disclosures for aleniglipron clinical data, amendments to a sales agreement, executive appointment and compensation matters, and shareholder-vote results. Proxy materials describe annual general meeting proposals, director elections, auditor ratification, advisory executive-compensation votes, board governance, and related shareholder procedures.
Structure Therapeutics Inc. appointed Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026. He brings more than 15 years of executive experience at biopharmaceutical companies including Metsera, Lyell Immunopharma, Myovant Sciences and Gilead Sciences, as well as prior law firm experience.
Under his employment agreement, Mr. Lang will receive a base salary of $560,000 per year and an annual discretionary bonus targeted at 40% of salary, with no pro‑ration for 2026. He will be granted an option to purchase 223,776 ordinary shares, time-based RSUs for 184,614 ordinary shares and performance-based RSUs for 46,155 ordinary shares, all subject to multi-year vesting tied to service and specified performance milestones through 2029.
Structure Therapeutics Inc. Chief Development Officer Ashley Hall reported compensation-related equity grants. Hall received an option to buy 59,073 ordinary shares at an exercise price of $16.82 per share, expiring on March 18, 2036, and now holds 59,073 derivative shares from this grant.
Hall was also awarded 47,706 restricted stock units, each representing one ordinary share, bringing direct ordinary share holdings to 155,187 shares after the award. The RSUs vest 1/4 each year on the anniversaries of March 1, 2026, while the option vests 1/4 on March 1, 2027 and monthly thereafter, subject to continued service.
Structure Therapeutics Inc. reported that Chief Medical Officer Blas Coll Crespo received equity compensation on March 19, 2026. He was granted an employee stock option for 93,984 Ordinary Shares at an exercise price of $16.82 per share, expiring in 2036.
He also received 75,897 Restricted Stock Units, each representing one Ordinary Share, vesting in four equal annual installments starting March 1, 2026, subject to continued service. Following these grants, he directly owns 280,878 Ordinary Shares. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. chief technology officer Yingli Ma reported equity compensation grants rather than market trades. Ma received an option to buy 40,278 Ordinary Shares at an exercise price of $16.82 per share, expiring in 2036, and 32,526 restricted stock units representing Ordinary Shares. The RSUs vest in four annual installments starting March 1, 2026, while the option vests 25% on March 1, 2027, with the remainder vesting monthly over three years. After the RSU grant, Ma directly holds 139,917 Ordinary Shares. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. reported that Chief Scientific Officer Xichen Lin received new equity awards. Lin was granted an employee stock option for 53,703 ordinary shares at an exercise price of $16.82 per share, expiring on March 18, 2036. One quarter of these option shares will vest on March 1, 2027, with the remainder vesting in 36 equal monthly installments, subject to continued service.
Lin was also awarded 43,368 restricted stock units, each representing one ordinary share. These RSUs vest one quarter annually on each anniversary of March 1, 2026, subject to continued service. Following the RSU grant, Lin directly holds 228,960 ordinary shares. The company notes that each American Depositary Share represents three ordinary shares.
Structure Therapeutics Inc. chief financial officer Yoon Jun reported receiving new equity compensation awards. He was granted employee stock options for 128,892 Ordinary Shares at an exercise price of $16.82 per share, expiring on March 18, 2036. One quarter of these options vest on March 1, 2027, with the remainder vesting in 36 monthly installments thereafter.
He also received 104,085 restricted stock units, each representing one Ordinary Share, vesting in four equal annual installments starting on March 1, 2026, subject to continued service. Following these awards, he held 1,401,656 Ordinary Shares directly and 1,554,586 Ordinary Shares indirectly through The Yoon Family Trust. The company’s Ordinary Shares may also be represented by ADSs, with each ADS equal to three Ordinary Shares.
Structure Therapeutics Inc.’s CEO, Raymond C. Stevens, received new equity awards. On March 19, 2026, he was granted an option to buy 322,230 Ordinary Shares at an exercise price of $16.82 per share, expiring on March 18, 2036.
He also received 260,217 restricted stock units, each representing one Ordinary Share, vesting one-quarter annually on each anniversary of March 1, 2026, subject to continued service. Following these grants, he holds 1,401,593 Ordinary Shares directly and 1,554,586 Ordinary Shares indirectly through the Stevens 2001 Revocable Trust. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics reported strong Phase 2 obesity data for its once-daily oral GLP‑1 receptor agonist aleniglipron from the ACCESS program. In the ACCESS II trial, placebo‑adjusted mean weight loss at 44 weeks reached 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg, with no evidence of weight‑loss plateau. An open‑label extension showed continued loss up to 16.2% (40.5 lbs) at 120 mg by week 56. Interim results from a body composition study using a lower 2.5 mg starting dose showed about 6.8% weight loss at a 20‑week median follow‑up and substantially fewer adverse‑event‑related discontinuations versus a 5 mg start. Across more than 625 participants, aleniglipron showed no drug‑induced liver injury, no persistent liver enzyme elevations, and no QTc prolongation. The company has an End‑of‑Phase 2 FDA meeting scheduled in the second quarter of 2026 and expects to start Phase 3 in the second half of 2026.
Structure Therapeutics Inc. chief medical officer Coll Crespo Blas reported a Form 4 showing a tax-related share disposition. On the vesting of a restricted share unit award, 11,826 Ordinary Shares were withheld by the company at $20.99 per share to cover income tax obligations. After this withholding transaction, Blas directly owned 204,981 Ordinary Shares. The footnotes explain that each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. Chief Technology Officer Ma Yingli reported a tax-related share disposition tied to vesting of a restricted share unit award. On this transaction date, 11,313 Ordinary Shares were withheld by the company at a price of $20.99 per share to cover income tax obligations. After this tax-withholding disposition, Ma Yingli directly owned 107,391 Ordinary Shares. The company notes that each American Depositary Share represents three Ordinary Shares.